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A generic capillary zone electrophoresis method was developed for the analysis of four proton pump 
inhibitors: omeprazole, pantoprazole, lansoprazole and rabeprazole. During preliminary analysis screening 
of phosphate buffers at different pH levels was performed, in order to determine the optimum pH domain 
suitable for the simultaneous determination of all studied compounds. A face centered central composite 
design was employed for the optimization of separation conditions. The effect of buffer concentration, pH 
and applied voltage was studied; resolution between peaks and migration time of the last compound were 
considered as responses. Other factors as system temperature, injection parameters, capillary length, were 
held constant during the optimization process. The optimized conditions consisted of 40mM phosphate 
background electrolyte at pH 5.0, +25 kV applied voltage and 20 °C temperature. The migration order 
of the analytes was as follows: rabeprazole, omeprazole, lansoprazole and pantoprazole. Full resolution 
of all analytes was achieved within 9 minutes. The method was validated and proved to be suitable in 
terms of repeatability, sensitivity, linearity, accuracy and robustness. Determinations from commercially 
available pharmaceutical formulation were performed for omeprazole; good reproducibility and recovery 
were obtained.
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INTRODUCTION
Proton pump inhibitors (PPIs) are currently the most 
effective and frequently used agents in acid suppression 
therapy. Their indications include disorders like dyspepsia, 
peptic ulcer, gastroesophageal reflux disease, Zollinger-
Ellison syndrome and eradication of Helicobacter pylori. 
PPIs act by blocking irreversibly the so called proton pump 
(hydrogen/potassium adenosine triphosphatase enzyme) 
localized in the luminal membrane of gastric parietal cells, 
producing an antisecretory effect for at least 24 hours 
(Strand, Kim, Peura, 2017).
The classical members of the PPIs, including 
omeprazole, pantoprazole, lansoprazole and rabeprazole 
are pyridinyl-methyl-sulfinyl-benzimidazole derivatives 
with a sulfoxide group attached at position 2 of the 
benzimidazole moiety. All of these compounds are weak 
bases having nearly equal pKa values around 4 (from 3.83 
for pantoprazole to 4.53 for rabeprazole) (Strand, Kim, 
Peura, 2017).
The chemical structures of the studied PPIs are 
presented in Figure 1.
In recent years, capillary electrophoresis (CE) has 
developed as an easily operable, cost-effective and an 
environmental friendly technique where the separation 
is based on the differences between the electrophoretic 
mobilities of the analytes in an electric field. Nowadays, CE 
represents an interesting alternative to high performance 
liquid chromatography (HPLC) methods in the analysis 
of pharmaceuticals (Deeb et al., 2014).
Recently, statistical experimental designs have 
been increasingly employed as a useful option in 
the development of analytical methods. The use of 
experimental design approaches enables the identification 
of significant analytical factors and interaction effects, 
and can help in establishing precisely the optimal 
combination of the experimental factors. An experimental 
design method is equipped to address several major 
experimental concerns for which the traditional “one 
factor ata time” (OFAAT) trial and error development iD
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technique is not suited (Orlandini, Gotti, Furlanetto, 
2014).
Experimental design methodologies used in 
analytical chemistry can be classified in screening 
designs (fractional factorial, Plackett-Burman etc.) 
and optimization designs (Central composite, Doelhert 
etc.). Central composite designs (CCDs) allow the 
estimation of linear, interaction and quadratic effects of 
the studied factors on the analytical response(s). Face 
centered central composite design is the simplest way to 
carry out a CCD, since each factor of interest has three 
experimental levels, by maintaining the design capability 
to use nonlinear models (Dejaegher, Mangelings, Vander 
Heyden, 2013).
In the last two decades several CE methods have 
been published for the analysis of PPIs (El-Kommos et 
al., 2015). A non-aqueous CE method has been reported 
for purity analysis of five different pyridinylmethyl-
sulfinyl-benzimidazole derivatives; N-methylformamide 
was found to have the best properties in respect of both 
electrophoretic behavior and high solubility of the model 
compounds (Tivesten et al., 1999). The determination 
of lansoprazole from capsules and enteric coated pellets 
have been achieved by CE using a 20 mM borate 
buffer at pH 8.7 as background electrolyte (Dogrukol-
Ak, Tuncel, Aboul-Enein, 2001). In another study a 
10mM sodium tetraborate buffer at pH 9.0 have been 
used for the determination of rabeprazole (Garcia et 
al., 2005). Simultaneous determination of omeprazole 
and lansoprazole has been achieved also using 50mM 
phosphate buffer at pH 9.0 (Lin, Wu, 2005). However, 
to our knowledge no generic CE method for the 
simultaneous determination of all four PPIs currently 
used in therapy has been published so far.
CE has been especially used successfully for the 
chiral analysis of PPIs. A validated CE method have 
been published for the chiral separation of three PPIs 
(pantoprazole, omeprazole and lansoprazole) using bovine 
serum albumin as chiral selector, in a phosphate buffer 
at pH 7.4; but because of strong absorption of the buffer 
system, the limits of detection were rather poor (Eberle, 
Hummel, Kuhn, 1997). Better results were obtained 
when using CD derivatives as chiral selectors. The use of 
β-CD as chiral selector in phosphate buffer at pH 4.0 has 
been investigated for the determination of omeprazole 
enantiomers from tablets; the results obtained were 
compared with the results obtained with a HPLC method 
(Bonato, Paias, 2004). The enantiomeric separation of 
omeprazole has been achieved also using methyl-β-CD, in 
strong acidic phosphate buffer at pH 2.2 (Nevado, Penalvo, 
Dorado, 2005). The enantiomers of omeprazole and its 
metabolite 5-hydroxyomeprazole have been separated 
by non-aqueous CE with heptakis-(2,3-di-O-methyl-
6-O-sulfo)-β-CD as chiral selector in an ammonium 
acetate buffer acidified with formic acid in methanol 
(Olsson et al., 2006). The chiral analysis of omeprazole 
and 5-hydroxyomeprazole, using aqueous CE and highly 
sufated-β-CD as chiral selector, with UV and MS detection 
have been also reported (Olsson, Marlin, Blomberg, 
2007). A validated method for combined analysis of the 
enantiomeric purity of both esomeprazole and related 
substances was based on the use of Tris–phosphate buffer 
and 2-hydroxypropyl-β-CD as chiral selector (Estevez 
et al. 2014). Chiral separation of pantoprazole has been 
achieved by CE using a mixed borate–phosphate buffer at 
pH 6.50 with sulfated-β-CD as chiral selector (Guan et al., 
2012). A method suitable for enantiomeric separation of 
pantoprazole, lansoprazole, omeprazole and tenatoprazole 
using a copper(II)-l-histidine complex and HP-β-CD as 
dual chiral selector system in a phosphate buffer have 
been also reported (Guan et al., 2014). An ephedrine-
based chiral ionic liquid, served as both chiral selector and 
FIGURE 1 - Chemical structures of the studied PPIs (* denotes the chiral centers).
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background electrolyte in an innovative non-aqueous CE 
system used for the enantioseparation of rabeprazole and 
omeprazole; ion-pair interaction and hydrogen bonding 
may be responsible for the main separation mechanism 
(Ma et al., 2010). A validated CE method has been 
reported for the quantitative determination of lansoprazole 
enantiomers from pharmaceutical formulations using 
phosphate buffer at pH 2.2, and β-CD as chiral selector 
(Nevado et al., 2009). A study regarding the enantiomeric 
separation of omeprazole and pantoprazole have been 
also published by our research group; the BGE consisted 
in a phosphate buffer at pH 2.5 and randomly methylated 
β-CD as chiral selector for omeprazole enantioseparation, 
and phosphate buffer at pH 7.0 and sulfobutyl ether-β-CD 
for the enantioseparation of pantoprazole, respectively 
(Hancu, Papp, Rusu, 2015).
The aim of this work was to develop a new simple, 
rapid and precise generic method for the determination 
of four PPIs (omeprazole, lansoprazole, rabeprazole and 
pantoprazole); to optimize the analytical conditions of 
the separation by an experimental design approach, and 
to evaluate the analytical performance of the developed 
method.
MATERIAL AND METHODS
Apparatus
Experiments were performed with an Agilent 1600 
CE system (Waldbronn, Germany) equipped with a diode-
array detector. Separations were performed using 48 cm 
length (effective length 40 cm) × 50 μm I.D. uncoated 
fused-silica capillaries (Agilent). Electropherograms 
were recorded and processed by Chemstation 7.01 
software (Agilent). Buffer solution pH was determined 
with a Terminal 740 pH-meter (Inolab, Germany). 
Design-Expert 7.0 statistical software (Stat-Ease, 
Minneapolis, USA) was used for experimental design 
method optimization. Microsoft Excel 2010 was used for 
statistical analysis during method validation.
Chemicals and reagents
Omeprazole was obtained from Alfa Aesar 
(Karlsruhe, Germany) while pantoprazole sodium 
from Cipla (Mumbai, India), both substances were of 
pharmaceutical grade; lansoprazole and rabeprazole 
sodium were USP reference standards (Rockville, USA). 
The following reagents of analytical grade were used: 
phosphoric acid (Chimopar, Bucharest, Romania), 
methanol, sodium hydroxide (LachNer, Neratovice, 
Czech Republic), disodium hydrogen phosphate, sodium 
dihydrogen phosphate and sodium metabisulfite (Merck, 
Darmstadt, Germany). Purified water was obtained using 
a Milli-Q Plus water-purification system (Millipore, 
Milford, USA). For determinations from commercially 
available pharmaceutical formulation Omez capsules (Dr 
Reddy’s, India) were used, each capsule containing 20 
mg omeprazole.
Sample preparation
Sample stock solutions were prepared by dissolving 
the analytes in methanol at a concentration of 1 mg mL−1; 
and subsequently diluted with the same solvent to 
appropriate concentrations. All buffers and sample 
solutions were filtered through 0.45 μm syringe filters 
and degassed for 5 minutes before use. The samples 
were introduced at the anodic end of the capillary by 
hydrodynamic injection, the detection taking place at the 
cathodic end.
For the analysis of commercial formulation the 
contents of ten capsules were mixed and powdered and 
an amount of powder equivalent to the weight of one 
capsule was dissolved in 100 mL methanol by sonication 
for 10 min. The solution was filtered through a 0.45 μm 
syringe filter, and diluted with methanol to the appropriate 
concentrations.
Electrophoretic conditions
Before first use, capillaries were washed for 30 
minutes with 0.1M sodium hydroxide solution and with 
water for 15 minutes followed by conditioning for 30 
minutes with the background electrolyte (BGE) used in 
the analysis. Between runs the capillaries were rinsed for 
2 minutes with 0.1M sodium hydroxide, then for 1 minute 
with water and finally for 2 minutes with the BGE. In the 
preliminary analysis we used “standard” electrophoretic 
conditions for a CE analysis: temperature 20°C, applied 
voltage +20 kV, injection pressure/time 50 mbar/2 sec., 
sample concentration 50μg mL−1. UV-detection was 
applied, detection wavelengths were set to 210, 240 and 
300nm, taking into consideration the absorption maxima 
of the analytes.
RESULTS AND DISCUSSION
Preliminary analysis
Ta k i n g  i n t o  c o n s i d e r a t i o n  t h e  f a c t  t h a t 
the simultaneous determination of all four studied 
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compounds demonstrates the capability of the method 
for the determination of these compounds possessing 
similar structural properties, conditions suitable for the 
simultaneous separation of all four analytes were searched. 
Preliminary experiments were conducted using phosphate 
buffers at different pH levels in the range of 2.5-9.0. The 
buffer concentration in the initial experiments was set to 
25 mM.
All PPIs have low stability in acidic condition; 
therefore some authors recommend the use of an 
antioxidant agent to prevent PPIs degradation (Bonato, 
Paias, 2004; Estevez et al., 2014). For this purpose 
5 mM sodium metabisulfite was added to acidic BGEs; 
this measure proved to be efficient in preventing analyte 
degradation during the electrophoretic procedures.
The pH of the BGE plays a major role in the 
selectivity of separation influencing not only the 
magnitude of the electroosmotic flow (EOF) but also the 
ionization grade of the analytes. Therefore the selection 
of an adequate pH domain can have a crucial effect on 
the simultaneous separation of analytes with similar 
physicochemical and structural properties.
Although all PPIs could be detected throughout 
the studied pH range (pH 2.5–9.0), simultaneous 
separation was achieved only when using phosphate 
buffer at pH 5.0. The migration order was the following: 
rabeprazole, omeprazole, lansoprazole and pantoprazole. 
The first two and the last two peaks have been baseline 
separated with high resolution values; but the resolution 
between omeprazole and lansoprazole was not 
satisfying (1.16), while the analysis time was above 
10 minutes. The electropherogram of the separation 
under initial electrophoretic conditions is presented in 
Figure 2.
Method optimization
In order to achieve baseline separation between 
omeprazole and lansoprazole and a shorter analysis time 
(<10 min.) while maintaining good resolution values 
between the other analytes, a face centered central 
composite design was applied. Based on the results 
of preliminary analysis, three analytical parameters 
were selected (BGE concentration, BGE pH and 
applied voltage); and their effect on two experimental 
responses (resolution value between omeprazole and 
lansoprazole, analysis time of the last migrating analyte) 
was verified.
Each experimental factor had three levels coded 
by +1, 0 and -1 (Table I). Other factors, considered to 
have minor influence on the studied responses, were kept 
constant during the experiments (system temperature 
20°C, hydrodynamic injection 50 mbar/2 sec, capillary 
effective length 40 cm). The experimental plan is 
summarized in Table II.
From the 20 runs performed, 6 were replicated 
injections in the center point of the design space (each 
factor being set on its medium level), 6 runs having the two 
factors set to medium, and one to +1 or -1; the remaining 
8 runs represented a 23 factorial design.
In order to evaluate the obtained experimental 
results, a second-order polynomial quadratic model was 
applied for both responses, as follows:
Y=β0+ β1*A+ β2*B+β3*C+ β4*AB+ β5*AC+ β6*BC + 
β7*A2+ β8*B2+ β9*C2,
where Y represents experimental response, A, B and C the 
experimental factors to be optimized, β0 is the intercept, 
FIGURE 2 - The separation of PPIs under inital electrophoretic conditions (analytical conditions: 25 mM phosphate buffer, 
5 mM sodium metabisulfite, pH 5.0. temperature 20 °C, applied voltage +20 kV, injection pressure/ time 50 mbar/2 sec., sample 
concentration 50 μg mL−1, UV detection 300 nm).
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β1-3 coefficients of linear, β4-6 coefficients of interaction and 
β7-9 coefficients of the quadratic terms.
ANOVA analysis was carried out to estimate the 
significance of the regression coefficients of the model. 
The insignificant model terms were deleted one by one, 
while the model was reevaluated after each deleted term.
The fitness of the model was evaluated by calculating 
the R2 and R2adj values. R2 expresses the fraction of the 
total variation explained by the model, while R2adj is an 
adjusted form of R2 by considering the model coefficients 
to be estimated and the total number of experiments 
performed.
The following final regression models were obtained 
in coded terms; for the resolution between omeprazole and 
lansoprazole:
R = 2.07 + 0.16 * A - 0.33 * B + 0.40 * C - 0.97 * A2 + 
0.39 * C2;
and for the migration time of pantoprazole/analysis time:
t = 11.80 - 0.40 * A + 0.56 * B - 3.97 * C + 0.71 * A2
The calculated R2and R2adjvalues (0.9205 and 
0.8921 for the first, 0.9768 and 0.9706 for the second 
model respectively) suggest that both of the estimated 
models have fit the experimental results.
In order to find an optimal combination of 
the studied analytical conditions for both measured 
responses, Derringer’s desirability function was applied. 
In this approach, experimental results are transformed 
in desirability values on a scale between 0 and 1, 0 
representing the most undesirable and 1 the most desired 
outcome of each response of interest. In our case, resolution 
had to be enhanced, and analysis time had to be minimized. 
TABLE I - Levels of studied factors in the face centered central 
composite design
Factor Levels
Coded 
form Natural form -1 0 1
A pH 4.5 5.0 5.5
B Buffer concentration (mM) 25 37.5 50
C Voltage (kV) 15 20 25
TABLE II - Experimental plan of the face centered central composite design
Standard order Injection order A  (pH)
B  
(buffer concentration, mM)
C  
(Voltage, kV)
4 1 5.5 50 15
11 2 5.0 25 20
1 3 4.5 25 15
5 4 4.5 25 20
18 5 5.0 37.5 20
20 6 5.0 37.5 20
17 7 5.0 37.5 20
15 8 5.0 37.5 20
10 9 5.5 37.5 20
14 10 5.0 37.5 25
9 11 4.5 37.5 20
13 12 5.0 37.5 15
7 13 4.5 50 25
3 14 4.5 50 15
2 15 5.5 25 15
12 16 5.0 50 20
6 17 5.5 25 25
16 18 5.0 37.5 20
19 19 5.0 37.5 20
8 20 5.5 50 25
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Global desirability was calculated as geometric mean of the 
individual desirability values, and then the overall optimum 
value was searched in the experimental space.
According to the obtained regression equations, 
quadratic terms were included in both models, but 
statistically significant interaction effects were not found. 
All three studied factors proved to influence significantly 
the resolution and the analysis time as well. By increasing 
the pH (factor A) of the buffer system the migration time 
of analytes decreased, as expected, but the resolution had 
an optimum pH value of 5.0. The analysis time increased 
when increasing buffer concentration (factor B), but 
an improvement in resolution and peak shapes was 
observed by increasing the ionic strength of the running 
buffer. Increasing the applied voltage (factor C) increased 
resolution and decreased analysis time. The effect of the 
buffer pH and applied voltage on resolution between 
omeprazole and lansoprazole, and on the analysis time of 
the last migrating analyte is presented in Figure 3.
A local desirability optimum was selected, based 
on the desirability function, for further determinations. 
The optimum analytical conditions consisted of 40 mM 
phosphate buffer concentration (containing 5 mM sodium 
metabisulfite) at pH 5.0 and + 25 kV applied voltage. The 
selected buffer concentration provided good peak shapes 
and resolution, which were in reasonable agreement with 
the increasing effect on analysis time. The pH value, 
which represented the medium level of the studied range, 
proved to be optimal for resolution of all analytes, while 
shorter analysis time was provided by the higher value of 
applied voltage.
Using these optimal analytical conditions good 
resolution values between omeprazole and lansoprazole 
(R=2.8, α=1.03) and short analysis time for the last 
migrating analyte, pantoprazole (8.1min.) were achieved. 
A typical electropherogram obtained from simultaneous 
separation of the four PPIs under the optimized conditions 
is presented in Figure 4. The numbers of theoretical plates 
FIGURE 3 - The effects of pH and applied voltage on the resolution value between omeprazole and lansoprazole (a) and on the 
analysis time of the last migrating analyte (b) respectively.
FIGURE 4 - The separation of PPIs under optimized electrophoretic conditions (analytical conditions: 40 mM phosphate buffer, 
5 mM sodium metabisulfite, pH 5.0. temperature 20 °C, applied voltage +25 kV, injection pressure/ time 50 mbar/2 sec., sample 
concentration 50 μg mL−1, UV detection 300 nm).
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were above 130000 for all four peaks, peak symmetry 
factors were between 0.9 and 1.1.
Method validation
The analytical performance of the developed method 
was evaluated according to ICH guidelines based on 
precision, accuracy, linearity, limit of detection (LOD), 
limit of quantification (LOQ) and robustness. For this 
purpose electrophoretic determinations were performed 
using the optimized analytical conditions on samples 
containing all of four studied compounds in the same 
concentration.
In order to investigate intra-day precision of the 
method, six consecutive injections (n =6) were made with 
a standard solution (c = 100 μg mL−1) of each drug under 
the optimized analytical conditions. RSD values were 
between 0.95 and 1.25% for migration times and between 
0.93 and 1.05% for peak areas. Inter-day precision was 
determined by performing six runs of a standard solution 
(c = 100 μg mL−1) under the optimized conditions over 
three consecutive days (n = 18). RSD values were between 
0.78 and 1.60% for migration times and between 1.02 and 
1.66% for peak areas.
Linearity of the method was investigated over 
the concentration range 20–150 μg mL−1 on the basis 
of six measurement points and three measurements per 
concentration; individual linear regression equations were 
calculated for each PPI. Correlation coefficients were 
above 0.99 for all four analytes (Table III).
The l imit  of  detection (LOD) and l imit  of 
quantification (LOQ) were estimated as standard deviation 
of regression equation/slope of the regression equation 
multiplied by 3.3 and 10, respectively (Table III).
Accuracy of the method was evaluated using 
recovery experiments by analyzing solutions of known 
concentrations within the linearity range at three levels 
(50, 100 and 150 μg mL-1); results of recovery study are 
summarized in Table IV.
The robustness of the method was demonstrated 
by studying the influence of the variation of several 
experimental parameters like buffer concentration (38-
42 mM), applied voltage (23-27 kV) and temperature 
(18-22 °C), changing only one of these variables each 
time, and monitoring variation of the migration times 
of the analytes. Only small acceptable deviations (RSD 
< 2%) were observed indicating that the robustness of the 
method was good.
The developed method was applied to the analysis 
of commercially available pharmaceutical preparations 
containing omeprazole. The prepared samples were 
analyzed in triplicate. Good agreement between the value 
claimed by the manufacturer and that determined by the 
CE method were obtained; the method presented good 
reproducibility (RSD - 1.17%), and recovery was in the 
range 95-105% of the declared content. No interference 
from the drug formulation excipients could be observed 
on the electropherogram.
CONCLUSIONS
Analytical methods for determination of PPIs are 
usually developed individually as expected because PPIs 
are not used in combination during therapy. However, the 
TABLE III - Regression and correlation data for the calibration curves of PPIs (concentration range 20–150 μg mL−1, n = 6)
Analyte Regression eqation Correlation coefficient LOD (µg/mL) LOQ (µg/mL)
Rabeprazole y = 0.0663x + 0.6866 R² = 0.993 11.11 33.67
Omeprazole y = 0.1986x + 0.516 R² = 0.996 7.88 23.88
Lansoprazole y = 0.1581x - 1.7724 R² = 0.994 10.50 31.81
Pantoprazole y = 0.2451x + 1.9406 R² = 0.995 5.94 17.99
TABLE IV - Accuracy results for the determination of PPIs
Compound
Theoretical 
concentration 
(µg/mL)
Found 
concentration 
(µg/mL)
RSD(%)
Rabeprazole 50 49.94 1.63
Omeprazole 49.16 0.70
Lansoprazole 50.61 1.12
Pantoprazole 49.38 1.10
Rabeprazole 100 101.06 1.61
Omeprazole 99.78 0.43
Lansoprazole 101.37 1.10
Pantoprazole 101.29 0.86
Rabeprazole 150 149.12 0.43
Omeprazole 149.11 0.38
Lansoprazole 150.20 1.48
Pantoprazole 149.56 0.93
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development of a rapid analytical procedure that will not 
be limited to the analysis of only one PPI could be very 
useful.
Using a face centered central composite design, 
proved to be a useful approach in the optimization of the 
CE experiment because a large variation in experimental 
parameters was evaluated, gaining valuable trend 
information, as this broad range may not have been 
covered if the one factor at a time approach had been 
utilized. Through experimental design, it was possible to 
determine the experimental conditions that would lead to 
an optimized separation without disregarding the effects 
at extreme set points.
The newly developed method enables  the 
simultaneous determination of the four studied analytes 
in less than 9 minutes using experimental conditions 
consisting of 40 mM phosphate buffer electrolyte at pH 
5.0, 5 mM sodium metabisulfite as antioxidant, +25 kV 
applied voltage, 20 0C system temperature, injection 
pressure/time 50 mbar/2 sec.
This study highlights the benefits of using 
universal methods for rapid quantitation of omeprazole, 
pantoprazole, lansoprazole and rabeprazole in a single run 
without the need for development of a separate and distinct 
method for each analyte.
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